AUSTIN, Texas, April 14, 2023 /PRNewswire/ — The main results of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) trial, a National Heart, Lung, and Blood Institute (NHLBI) sponsored trial were presented. Although the results of the trial are not final, they offer valuable information…Read More
Related Posts
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ Assay Across…
SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical…
RPT NGOs Hope New Research Helps US Congress Fight Serious Cancer Drug Shortages UrduPoint
WASHINGTON (UrduPoint News / Sputnik - 21st June, 2023) Data gathered on the significant drug shortages oncology patients are facing in the United States hopefully can help the Biden administration…
FDA skeptical of experimental ALS treatment pushed by patient advocates
WASHINGTON (AP) -- The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig's disease, the culmination of a yearslong lobbying effort by…
